Therefore, the limitations of these clinical agents need to be improved, and the development of new enhancive combination strategies is key to effectively remodeling the tumor microenvironment to increase CD8+ T cell tumor infiltration in the CRC tumor microenvironment in order to improve the response to PD-1/PD-L1 blockade immunotherapies. The gene discussed is CD8A; the disease is neoplasm.